Pyxis Oncology annual r&d spending
2020
2021
2022
2023
2024
2025
Pyxis Oncology R&D Spending Growth & History (PYXS)
Pyxis Oncology's r&d spending was $73.7M for fiscal 2025.
View full Pyxis Oncology company overviewPyxis Oncology annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $73.7M | $14.9M | +25.45% |
| 2024 | 2024-12-31 | $58.7M | $9.2M | +18.47% |
| 2023 | 2023-12-31 | $49.6M | −$36.5M | −42.43% |
| 2022 | 2022-12-31 | $86.1M | $35.1M | +68.70% |
| 2021 | 2021-12-31 | $51.1M | $42.0M | +464.26% |
| 2020 | 2020-12-31 | $9.0M | — | — |
Pyxis Oncology quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.1M | −$1.1M | −6.28% |
| Q1 2026 | 2026-03-31 | $20.0M | $2.9M | +17.24% |
| Q4 2025 | 2025-12-31 | $21.7M | $7.7M | +54.81% |
| Q3 2025 | 2025-09-30 | $17.8M | $67,000 | +0.38% |
| Q2 2025 | 2025-06-30 | $17.1M | $3.2M | +22.79% |
| Q1 2025 | 2025-03-31 | $17.0M | $4.0M | +30.82% |
| Q4 2024 | 2024-12-31 | $14.0M | $2.4M | +20.82% |
| Q3 2024 | 2024-09-30 | $17.7M | $3.1M | +20.79% |
| Q2 2024 | 2024-06-30 | $14.0M | $2.6M | +22.49% |
| Q1 2024 | 2024-03-31 | $13.0M | $1.1M | +9.48% |
| Q4 2023 | 2023-12-31 | $11.6M | −$18.2M | −61.12% |
| Q3 2023 | 2023-09-30 | $14.7M | −$4.3M | −22.84% |
| Q2 2023 | 2023-06-30 | $11.4M | −$5.8M | −33.66% |
| Q1 2023 | 2023-03-31 | $11.9M | −$8.2M | −40.71% |
| Q4 2022 | 2022-12-31 | $29.9M | $22.6M | +313.15% |
| Q3 2022 | 2022-09-30 | $19.0M | $11.2M | +142.50% |
| Q2 2022 | 2022-06-30 | $17.2M | $14.0M | +435.73% |
| Q1 2022 | 2022-03-31 | $20.1M | −$12.7M | −38.76% |
| Q4 2021 | 2021-12-31 | $7.2M | — | — |
| Q3 2021 | 2021-09-30 | $7.8M | $5.4M | +223.67% |
| Q2 2021 | 2021-06-30 | $3.2M | — | — |
| Q1 2021 | 2021-03-31 | $32.8M | — | — |
| Q3 2020 | 2020-09-30 | $2.4M | — | — |
Pyxis Oncology r&d spending trends
Over the last five fiscal years, Pyxis Oncology's r&d spending increased from $9.0M to $73.7M, a change of $64.6M. The latest reported quarter, Q2 2026, shows $16.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pyxis Oncology source filings ↗